Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy 
in EGFR-mutant lung cancer

Schöttle, Jakob; Chatterjee, Sampurna; Volz, Caroline; Siobal, Maike; Florin, Alexandra; Rokitta, Dennis; Hinze, Yvonne; Dietlein, Felix; Plenker, Dennis; König, Katharina; Albus, Kerstin; Heuckmann, Johannes M.; Rauh, Daniel; Franz, Thomas; Neumaier, Bernd; Fuhr, Uwe; Heukamp, Lukas C.; Ullrich, Roland T.

doi:10.18632/oncotarget.6276

Local TagsRelease HistoryDetailsSummary

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer

Schöttle, J., Chatterjee, S., Volz, C., Siobal, M., Florin, A., Rokitta, D., et al. (2015). Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget, 6(36), 38458-38468. doi:10.18632/oncotarget.6276.

Item is Released

show all hide all

Basic

show hide

Item Permalink: https://hdl.handle.net/11858/00-001M-0000-0029-2FEE-F Version Permalink: https://hdl.handle.net/11858/00-001M-0000-0029-2FEF-D

Genre: Journal Article

Files

show Files

Locators

show

Creators

show

hide

Creators:
Schöttle, Jakob¹, Author
Chatterjee, Sampurna², Author
Volz, Caroline, Author
Siobal, Maike³, Author
Florin, Alexandra, Author
Rokitta, Dennis, Author
Hinze, Yvonne⁴, Author
Dietlein, Felix³, Author
Plenker, Dennis, Author
König, Katharina, Author
Albus, Kerstin, Author
Heuckmann, Johannes M.³, Author
Rauh, Daniel, Author
Franz, Thomas, Author
Neumaier, Bernd⁵, Author
Fuhr, Uwe, Author
Heukamp, Lukas C., Author
Ullrich, Roland T.¹, Author

Affiliations:
1Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149663
2In-vivo-NMR, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149666
3Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149656
4Bio-MS, Core Facilities, Max Planck Institute for Biology of Ageing, Max Planck Society, ou_1942305
5Radiochemistry, Scientific Services and Development, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149672

Content

show

Details

show

hide

Language(s): eng - English

Dates: Date issued: 2015

Publication Status: Issued

Pages: -

Publishing info: -

Table of Contents: -

Rev. Type: Peer

Identifiers: DOI: 10.18632/oncotarget.6276

Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show

hide

Title: Oncotarget

Source Genre: Journal

Creator(s):

Affiliations:

Publ. Info: -

Pages: - Volume / Issue: 6 (36) Sequence Number: - Start / End Page: 38458 - 38468 Identifier: ISSN: 19492553